Table 2.
General characteristics of the Swedish cohort
| N | All N = 955 | Men N = 259 (27.1%) | Women N = 696 (72.9%) | |||
|---|---|---|---|---|---|---|
| Age, years | 955 | 66.38 (12.90) | 69.39 (12.13) | 65.27 (13.00) | ||
| Disease duration, years | 955 | 15.55 (3.85) | 15.72 (3.90) | 15.48 (3.84) | ||
| RF pos | 939 | 622 (65.1) | 174 (67.2) | 448 (64.4) | ||
| TJC | 955 | 5.20 (6.60) | 4.36 (6.20) | 5.51 (6.70) | ||
| SJC | 955 | 3.06 (4.90) | 2.53 (4.72) | 3.26 (4.94) | ||
| PatGa | 955 | 3.04 (2.43) | 2.82 (2.35) | 3.12 (2.50) | ||
| Pain | 923 | 3.42 (2.54) | 2.94 (2.50) | 3.60 (2.54) | ||
| Fatigue | 927 | 4.08 (2.85) | 3.40 (2.63) | 4.33 (2.90) | ||
| HAQ | 945 | 0.52 (0.55) | 0.41 (0.53) | 0.56 (0.56) | ||
| EQ5D | 921 | 0.72 (0.25) | 0.77 (0.21) | 0.70 (0.25) | ||
| Cardiovascular disease*1 | 934 | 471 (49.3) | 148 (57.1) | 323 (46.4) | ||
| Pulmonary disease*2 | 919 | 113 (11.8) | 35 (13.5) | 78 (11.2) | ||
| Medical treatment | ||||||
| No DMARD or CS | 884 | 146 (15.3) | 35 (13.5) | 111 (15.9) | ||
| cDMARD ± CS | 884 | 387 (40.5) | 109 (42.1) | 278 (39.9) | ||
| bDMARD ± CS | 884 | 293 (30.7) | 66 (25.5) | 227 (32.6) | ||
| Only CS | 884 | 58 (6.1) | 23 (8.9) | 35 (5.0) | ||
| Lifestyle factors | ||||||
| Tobacco use | 955 | 163 (17.1) | 63 (24.3) | 100 (14.4) | ||
| BMI, kg/m2 | 955 | 25.93 (4.73) | 26.25 (3.62) | 25.81 (5.10) | ||
| BMI, kg/m2 | < 25.0 | 955 | 444 (46.5) | 99 (38.2) | 345 (49.6) | |
| BMI, kg/m2 | 25.0–29.9 | 955 | 357 (37.4) | 125 (48.3) | 232 (33.3) | |
| BMI, kg/m2 | ≥ 30 | 955 | 154 (16.1) | 35 (13.5) | 119 (17.1) | |
| Alcohol above national limits*3 | 955 | 185 (19.4) | 52 (20.1) | 133 (19.1) | ||
| Physical activity < 150 min/week (MVPA) | 955 | 492 (51.5) | 134 (51.7) | 358 (51.4) | ||
Data presented as mean (SD) or n (%)
RF, rheumatoid factor; TJC, tender joint count (0–28); SJC, swollen joint count (0–28); PatGa, patient global assessment (0–10, best to worst); pain (0–10, best to worst); fatigue (0–10, best to worst); HAQ, Health Assessment Questionnaire (0–3, best to worst); EQ5D, Euroqol Five Dimensions (0–1, worst to best); cDMARD, conventional disease-modifying antirheumatic drugs (with or without corticosteroids); bDMARD, biological disease-modifying antirheumatic drugs (with or without corticosteroids); CS, corticosteroids; BMI, body mass index
*1Includes hypertension, hypercholesterolemia, angina pectoris, myocardial infarction, thrombosis and stroke
*2Includes asthma, chronic obstructive pulmonary disease and emphysema
*3AUDIT-C > 4 points for women and > 5 points for men